Global Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts (2016-2020)

Global Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts (2016-2020)

Scope of the Report

The report titled “Global Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts (2016-2020)”, provides and in-depth analysis of the global CINV market and respective drugs. The report gives an insight of the global CINV market by 5-HT3 and NK-1 drug receptor antagonists.

The report also includes the analysis of North American CINV market. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global CINV market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The competition in global CINV market is fragmented as the specific treatment for CINV is still at a nascent stage with several drugs by multiple competitors already thriving the market and some are under formulation.

The key players of the global CINV market, Heron Therapeutics, Inc., Merck & Co., Inc., Novartis AG and TESARO, Inc. are also profiled with their financial information and respective business strategies

Country Coverage

North America

Company Coverage

Heron Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG

Executive Summary

Chemotherapy induced nausea and vomiting (CINV) is the most dreaded side-effect of chemotherapy among the cancer patients. Therefore, sometimes patients either do not undergo the chemotherapy or discontinue in the prior year of treatment. CINV is also of various types such as acute, breakthrough, delayed, anticipatory and refractory. HEC and MEC regimens cause the CINV. Several treatments of CINV are on the verge of emergence such as 5-HT3 receptor antagonist, NK-1 blocker, corticosteroids, cannabinoids and dopamine antagonists. However, there are several unmet medical needs in the field of HEC regimen of delayed CINV.

Global CINV market has increased at a significant CAGR during the years 2013-2015 and projections are made that the market would rise tremendously in the next four years i.e. 2016-2020. The CINV market is expected to increase due to growth in global cancer incidence, increasing health expenditure and the increasing outbreak of factors working towards causing cancer. Yet, the market faces some challenges such as discontinuation of chemotherapy treatment, several unmet medical needs, no drugs for the HEC regimen in the delayed CINV, etc.

1. Executive Summary
2. Introduction
2.1 Chemotherapy: An Overview
2.1.1 Side-Effects of Chemotherapy
Table 1: Side-Effects of Chemotherapy
2.1.2 Delivery Methods of Chemotherapy
Table 2: Delivery Methods of Chemotherapy
2.1.3 Types of Chemotherapy Drugs
Table 3: Types of Chemotherapy Drugs
2.1.4 Pros & Cons of Chemotherapy
Table 4: Pros & Cons of Chemotherapy
2.2 CINV: An Overview
2.2.1 Types of CINV
Table 5: Types of CINV
2.2.2 CINV Mechanism
Table 6: CINV Mechanism
2.2.3 Regimens Causing CINV
Table 7: Regimens Causing CINV
Table A : Regimens Causing CINV
2.2.4 Treatment/Prevention of CINV
Table 8: Treatment/Prevention of CINV
3. Global Market Analysis
3.1 Global CINV Market: An Analysis
3.1.1 Global CINV Market Opportunity
Table 9: Global CINV Market Opportunity; 2015
3.1.2 Global CINV Market by Value
Table 10: Global CINV Market by Value; 2013-2015 (US$ Billion)
Table 11: Global CINV Market by Value; 2016-2020 (US$ Billion)
3.2 Global NK-1 Drug Receptor Antagonist Market
3.2.1 Global VARUBI Sales
Table 12: Global VARUBI Sales; 2016-2020 (US$ Million)
3.2.2 Global Emend (Injectable) Sales
Table 13: Global Emend (Injectable) Sales; 2009-2015 (Thousand)
3.3 Global 5-HT3 Drug Receptor Antagonist Market
3.3.1 Global Aloxi (Injectable) Sales
Table 14: Global Aloxi (Injectable) Sales; 2009-2015 (Million)
3.3.2 Global Granisetron (Injectable) & Ondansetron (Injectable) Sales
Table 15: Global Granisetron Sales; 2009-2015 (Thousand)
Table 16: Global Ondansetron Sales; 2009-2015 (Million)
4. Regional Market Analysis
4.1 North America CINV Market: An Analysis
4.1.1 North America CINV Market by Value
Table 17: North America CINV Market by Value; 2013-2015 (US$ Million)
Table 18: North America CINV Market by Value; 2016-2020 (US$ Million)
4.1.2 US CINV Market Opportunity
Table 19: US CINV Market Opportunity; 2015
4.1.3 US CINV Market by Drugs Prescription
Table 20: US CINV Market by Drugs Prescription; 2015 (Million)
Table 21: US 5-HT3 Drug Prescription by Segments; 2015
5. Market Dynamics
5.1 Growth Driver
5.1.1 Rising Global Incidence of Cancer
Table 22: Global Incidence of Cancer; 2012-2019 (Million)
5.1.2 Widening Causes of Cancer
Table 23: Causes of Cancer; 2014
5.1.3 Rising Global Healthcare Expenditure
Table 24: Global Healthcare Expenditure; 2009-2014 (US$ Trillion)
5.2 Challenges
5.2.1 No Drug for Delayed CINV-HEC Regimens
Table B: Drugs for CINV
5.2.2 Unmet Medical Needs
Table 25: Unmet Needs in Prevention of CINV
5.2.3 Discontinuation of Chemotherapy Treatment
Table 26: Discontinuation of Chemotherapy Treatment
5.2.4 Under-Utilized Antagonists
5.3 Market Trends
5.3.1 Breakthrough CINV
Table 27: Breakthrough CINV by Regimen; 2015 (Percentage, %)
Table 28: Breakthrough CINV by Occurrence; 2015
5.3.2 Side-Effects of Chemotherapy
Table C: Side-Effects of Chemotherapy
5.3.3 Need for Inclusion of NK1 Blocker
5.3.4 Availability of Generic Products
6. Competitive Landscape
6.1 CINV Market Players by Agents Approved and In Development
Table D: CINV Market Players by Agents Approved and In Development
6.2 Global CINV Product : NK1 Receptor Antagonists
Table E: Comparison of NK1 Receptor Antagonists
7. Company Profile
7.1 Heron Therapeutics, Inc.
7.1.1 Business Overview
7.1.2 Financial Overview
Table 29: Heron Net Loss; 2011-2015 (US$ Billion)
Table 30: Heron Research & Development Expenditure; 2011-2015 (US$ Million)
7.1.3 Business Strategy
7.2 Merck & Co., Inc.
7.2.1 Business Overview
7.2.2 Financial Overview
Table 31: Merck & Co., Inc. Sales; 2011-2015 (US$ Billion)
Table 32: Merck & Co., Inc. Sales by Segments; 2015
7.2.3 Business Strategy
7.3 Novartis AG
7.3.1 Business Overview
7.3.2 Financial Overview
Table 33: Novartis AG Business Segments
Table 34: Novartis AG Total Sales; 2011-2015 (US$ Billion)
Table 35: Novartis AG Sales by Segments; 2015
7.3.3 Business Strategy
7.4 TESARO, Inc.
7.4.1 Business Overview
7.4.2 Financial Overview
Table 36: TESARO, Inc. Net Loss; 2011-2015 (US$ Million)
Table 37: TESARO, Inc. Research & Development Expenditure; 2011-2015 (US$ Million)
7.4.3 Business Strategy

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook